VET3-TGI

AXP000106.1 · Oncolytic virus

Platform
vaccinia virus (VET platform)
Originator
KaliVir Immunotherapeutics
Sponsor
KaliVir Immunotherapeutics

Names

NameTypeSource
VET3-TGIpreferred name, codecurator, ncit

Virus

Role
Oncolytic
Family
Poxviridae
Virus
vaccinia virus (NCBI Taxonomy 10245)
Replication
conditionally replicating
Modifications
thymidine kinase deleted; engineered for enhanced extracellular enveloped virus production (details not fully disclosed)
Transgenes
IL12A, IL12B, TGF-beta inhibitor
Route
intravenous, intratumoral
Source
evidence

Cross-references

NCI Thesaurus
C211499

Approvals

No regulatory approval recorded.

Clinical trials (1)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT06444815A Study of VET3-TGI in Patients With Solid TumorsRecruitingPhase 12024-09-162027-09-3060Cervical Cancer; Cutaneous Squamous Cell Carcinoma (CSCC); Head and Neck Squamous Cell Carcinoma; Kidney Cancer; Melanoma Stage IV; Merkel Cell Carcinoma of Skin; Mesothelioma; Microsatellite Stable Colorectal Cancer; Non-small Cell Lung Cancer; Renal Cell Carcinoma; Solid Tumor, Adult; Squamous Cell Carcinoma; Urothelial Carcinoma Bladder

Recent changes

No changes recorded in its trials yet.

Clinical papers

No confirmed clinical papers yet.

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 42767770Intravenously deliverable oncolytic virus VET3-TGI favorably alters the tumor microenvironment.Journal for immunotherapy of cancer2026name in title: VET3-TGI

Notes

Vaccinia Enhanced Template platform virus expressing IL-12 and a TGF-beta inhibitor; phase 1/1b alone and with atezolizumab (NCT06444815, recruiting since June 2024).

How to cite

VET3-TGI (AXP000106.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000106.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.